1. Scrip
  2. >>Business
  3. >>Financing

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

 
• By Jessica Merrill

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

IV1912_Scrip-100_Upheaval_572140570_1200.jpg
Change on the horizon for big pharma • Source: Shutterstock

It was generally a steady year in the top pharmaceutical companies, based on full year 2018 pharma sales. There were notable fluctuations, but nothing like what will be in store for the industry if the big deals and M&A that have been announced in 2019 move forward as anticipated. The industry is poised for a major reshaping in the years ahead.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings

 
• By Mandy Jackson

There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.

Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise

 
• By Mandy Jackson

Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.